• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Bruker Corporation

    9/4/25 6:01:59 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BRKR alert in real time by email
    FWP 1 ny20054907x3_fwp.htm FWP
    Pricing Term Sheet
    Free Writing Prospectus
    dated as of September 3, 2025
    Filed pursuant to Rule 433
       
     
    Supplementing the
     
    Preliminary Prospectus Supplement dated September 2, 2025 to the
     
    Prospectus dated June 2, 2023
     
    Registration No. 333-272381


    Bruker Corporation

    2,400,000 Shares of 6.375% Mandatory Convertible Preferred Stock, Series A

    The information in this pricing term sheet should be read together with Bruker Corporation’s preliminary prospectus supplement dated September 2, 2025 (the “Preliminary Prospectus Supplement”), including the documents incorporated by reference therein and the related base prospectus dated June 2, 2023, each filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, Registration No. 333-272381. Terms not defined in this pricing term sheet have the meanings given to such terms in the Preliminary Prospectus Supplement. The information in this pricing term sheet supersedes the information in the Preliminary Prospectus Supplement and the accompanying prospectus to the extent it is inconsistent with the information in the Preliminary Prospectus Supplement or the accompanying prospectus.  All references to dollar amounts are references to U.S. dollars.
     
    Issuer:
    Bruker Corporation, a Delaware corporation.

    Ticker / Exchange for the Issuer’s
    Common Stock:

    BRKR / The Nasdaq Global Select Market (“Nasdaq”).
    Pricing Date:
    September 3, 2025.

    Trade Date:
    September 4, 2025.

    Settlement Date:
    September 8, 2025, which is the second business day after the initial trade date for the Mandatory Convertible Preferred Stock (this settlement cycle being referred to as “T+2”). Under Rule 15c6-1 under the Exchange Act, trades in the secondary market generally must settle in one business day, unless the parties to the trade expressly agree otherwise. Accordingly, purchasers who wish to trade shares of Mandatory Convertible Preferred Stock before the business day before the settlement date must, because the Mandatory Convertible Preferred Stock initially will settle T+2, specify an alternate settlement cycle at the time of such trade to prevent a failed settlement. Those purchasers should consult their advisors.

    Securities Offered:
    2,400,000 shares of the Issuer’s 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the “Mandatory Convertible Preferred Stock”).

    Over-Allotment Option:
    Up to 360,000 additional shares of the Mandatory Convertible Preferred Stock.

    Public Offering Price:
    $250.00 per share of the Mandatory Convertible Preferred Stock.

    Underwriting Discount:
    $6.8750 per share of the Mandatory Convertible Preferred Stock.

    Liquidation Preference:
    $250.00 per share of the Mandatory Convertible Preferred Stock.

    Dividends:
    6.375% of the liquidation preference of $250.00 per share of the Mandatory Convertible Preferred Stock per annum.
     
    The expected dividend payable on the first Dividend Payment Date (as defined below) is approximately $3.6745 per share of the Mandatory Convertible Preferred Stock. Each subsequent dividend is expected to be approximately $3.9844 per share of the Mandatory Convertible Preferred Stock.


    Dividend Record Dates:
    The February 15, May 15, August 15 and November 15 immediately preceding the relevant Dividend Payment Date.

    Dividend Payment Dates:
    March 1, June 1, September 1 and December 1 of each year, commencing on December 1, 2025, and ending on, and including, September 1, 2028.

    Mandatory Conversion Date:
    The second business day immediately following the last trading day of the 20 consecutive trading day period beginning on, and including, the 21st scheduled trading day immediately preceding September 1, 2028. The Mandatory Conversion Date is expected to be September 1, 2028.

    Initial Price:
    $250.00, divided by the Maximum Conversion Rate (as defined below), which quotient is initially equal to approximately $29.35.

    Threshold Appreciation Price:
    $250.00, divided by the Minimum Conversion Rate (as defined below), which quotient is initially equal to approximately $35.95, which represents an approximately 22.50% appreciation over the Initial Price.

    Floor Price:
    $10.27 (approximately 35% of the Initial Price), subject to adjustment as described in the Preliminary Prospectus Supplement.

    Conversion Rate:
    Upon conversion on the Mandatory Conversion Date, the conversion rate for each share of the Mandatory Convertible Preferred Stock will be not more than 8.5179 shares of the Issuer’s common stock (the “Maximum Conversion Rate”) and not less than 6.9534 shares of the Issuer’s common stock, (the “Minimum Conversion Rate”), depending on the Applicable Market Value of the Issuer’s common stock and subject to certain anti-dilution adjustments.

     
    The following table illustrates hypothetical conversion rates per share of the Mandatory Convertible Preferred Stock, subject to certain anti-dilution adjustments described in the Preliminary Prospectus Supplement:

     
    Assumed Applicable
    Market Value of
    the Issuer’s common stock
    Assumed Conversion Rate
    (number of shares of
    the Issuer’s common
    stock to be received upon
    mandatory conversion
    of each share of the Mandatory
    Convertible Preferred Stock)
     
    Greater than the Threshold Appreciation Price
    6.9534 shares of the Issuer’s common stock

     
    Equal to or less than the Threshold Appreciation Price but greater than or equal to the Initial Price

    Between 6.9534 and 8.5179 shares of the Issuer’s common stock, determined by dividing $250.00 by the Applicable Market Value

     
    Less than the Initial Price
    8.5179 shares of the Issuer’s common stock

    Early Conversion at the Option of the Holder:
    Other than during a Fundamental Change Conversion Period, at any time prior to September 1, 2028, holders of the Mandatory Convertible Preferred Stock have the option to elect to convert their shares of the Mandatory Convertible Preferred Stock, in whole or in part (but in no event in increments of less than one share of the Mandatory Convertible Preferred Stock), into shares of the Issuer’s common stock at the Minimum Conversion Rate, subject to adjustment as described in the Preliminary Prospectus Supplement.

    Conversion at the Option of the Holder upon Fundamental Change; Fundamental Change Dividend Make-Whole Amount:
    If a Fundamental Change occurs on or prior to September 1, 2028, holders of the Mandatory Convertible Preferred Stock will have the right to convert their shares of the Mandatory Convertible Preferred Stock, in whole or in part (but in no event in increments of less than one share of the Mandatory Convertible Preferred Stock), into shares of the Issuer’s common stock (or Units of Exchange Property (as described in the Preliminary Prospectus Supplement)) at the Fundamental Change Conversion Rate.

     
    Holders who convert their Mandatory Convertible Preferred Stock within the Fundamental Change Conversion Period will also receive a Fundamental Change Dividend Make-Whole Amount and, to the extent there is any, the Accumulated Dividend Amount.

     
    The following table sets forth the Fundamental Change Conversion Rate per share of the Mandatory Convertible Preferred Stock based on the Fundamental Change Effective Date and the Fundamental Change Stock Price:


    Fundamental Change Stock Price
    Fundamental Change
    Effective Date
    $5.00
    $10.00
    $15.00
    $20.00
    $25.00
    $29.35
    $32.50
    $35.95
    $40.00
    $50.00
    $60.00
    $70.00
    $85.00
    $100.00
    September 8, 2025
    7.2883
    7.5358
    7.4283
    7.2916
    7.1767
    7.0984
    7.0528
    7.0116
    6.9728
    6.9087
    6.8725
    6.8517
    6.8359
    6.8292
    September 1, 2026
    7.6794
    7.8824
    7.7459
    7.5567
    7.3877
    7.2692
    7.1992
    7.1360
    7.0768
    6.9801
    6.9275
    6.8987
    6.8777
    6.8693
    September 1, 2027
    8.0577
    8.2325
    8.1493
    7.9333
    7.6866
    7.4944
    7.3773
    7.2713
    7.1737
    7.0258
    6.9573
    6.9265
    6.9097
    6.9055
    September 1, 2028
    8.5179
    8.5179
    8.5179
    8.5179
    8.5179
    8.5179
    7.6923
    6.9541
    6.9534
    6.9534
    6.9534
    6.9534
    6.9534
    6.9534

     
    The exact Fundamental Change Stock Price and Fundamental Change Effective Date may not be set forth in the table, in which case:

      ●
    if the Fundamental Change Stock Price is between two Fundamental Change Stock Prices in the table or the Fundamental Change Effective Date is between two Fundamental Change Effective Dates in the table, the Fundamental Change Conversion Rate will be determined by a straight-line interpolation between the Fundamental Change Conversion Rates set forth for the higher and lower Fundamental Change Stock Prices and the earlier and later Fundamental Change Effective Dates, as applicable, based on a 365- or 366-day year, as applicable;

      ●
    if the Fundamental Change Stock Price is in excess of $100.00 per share (subject to adjustment in the same manner as the Fundamental Change Stock Prices set forth in the column headings of the table above as described in the Preliminary Prospectus Supplement), then the Fundamental Change Conversion Rate will be the Minimum Conversion Rate; and

      ●
    if the Fundamental Change Stock Price is less than $5.00 per share (subject to adjustment in the same manner as the Fundamental Change Stock Prices set forth in the column headings of the table above as described in the Preliminary Prospectus Supplement), then the Fundamental Change Conversion Rate will be the Maximum Conversion Rate.

    Discount Rate for Purposes of Fundamental Change Dividend Make-Whole Amount:

    The discount rate for purposes of determining the Fundamental Change Dividend Make-Whole Amount is 7.30% per annum.
    Use of Proceeds:
    The Issuer estimates that the net proceeds from the offering will be approximately $582.0 million (or approximately $669.5 million if the underwriters exercise their over-allotment option to purchase additional shares of Mandatory Convertible Preferred Stock in full), in each case after deducting the underwriting discounts and commissions and estimated offering expenses payable by it.

     
    The Issuer intends to use the net proceeds from the offering to strengthen the balance sheet and enhance strategic flexibility by  repaying (i) its 2019 Term Loan Agreement in full, (ii) outstanding borrowings under its 2024 Revolving Credit Agreement in full and (iii) a portion of its loan due 2027 under its 2024 Term Loan Agreements.

     
    If the underwriters exercise their over-allotment option to purchase additional shares of Mandatory Convertible Preferred Stock, the Issuer intends to use the net proceeds from the sale of such additional shares of Mandatory Convertible Preferred Stock for general corporate purposes, which may include further payments of outstanding indebtedness, funding working capital, capital expenditures, potential future acquisitions and investments, investments in or loans to its subsidiaries, share repurchases and dividends.

    Listing:
    The Issuer intends to apply to list the Mandatory Convertible Preferred Stock on the Nasdaq under the symbol “BRKRP.” If the application is approved, the Issuer expects trading in the Mandatory Convertible Preferred Stock on the Nasdaq to begin within 30 days after the Mandatory Convertible Preferred Stock is first issued. However, there can be no assurance that the Mandatory Convertible Preferred Stock will be listed, and if listed, that it will continue to be listed. Listing the Mandatory Convertible Preferred Stock on the Nasdaq does not guarantee that a trading market will develop or, if a trading market does develop, the depth or liquidity of that market or the ability of holders to sell their Mandatory Convertible Preferred Stock easily.

    CUSIP / ISIN for the Mandatory Convertible Preferred Stock:

    116794 207/US1167942077
    Joint Book-Running Managers:

    J.P. Morgan Securities LLC
    BofA Securities, Inc.

    Co-Manager:
    PNC Capital Markets LLC
    _________________________________

    The Issuer has filed a registration statement (including the Preliminary Prospectus Supplement and the accompanying prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the Preliminary Prospectus Supplement and the accompanying prospectus in that registration statement and the other documents the Issuer has filed with the SEC for more complete information about the Issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC’s website at http://www.sec.gov. Alternatively, copies may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected] and [email protected]; or BofA Securities, Inc., Attn: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, email: [email protected], telephone: 1-800-294-1322.

    ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED.  SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM.


    Get the next $BRKR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BRKR

    DatePrice TargetRatingAnalyst
    5/22/2025$40.00Buy → Neutral
    Citigroup
    12/19/2024$72.00Buy
    Guggenheim
    12/10/2024$66.00Neutral
    UBS
    12/5/2024$60.00Sell → Neutral
    Goldman
    10/15/2024$75.00Overweight
    Barclays
    9/30/2024Outperform → Peer Perform
    Wolfe Research
    8/28/2024$78.00Overweight
    Wells Fargo
    6/3/2024$85.00Buy
    Jefferies
    More analyst ratings

    $BRKR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bruker Announces Pricing of Public Offering of $600 Million of 6.375% Mandatory Convertible Preferred Stock

    Bruker Corporation ("Bruker") (NASDAQ:BRKR) today announced the pricing of its previously announced public offering of $600.0 million of 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the "Mandatory Convertible Preferred Stock"). Bruker has granted the underwriters a 30-day option to purchase up to an additional $90.0 million of Mandatory Convertible Preferred Stock. The offering is expected to close on or about September 8, 2025, subject to customary closing conditions. Bruker estimates that the net proceeds from this offering will be approximately $582.0 million (or approximately $669.5 million if the underwriters exercise their option to purchase Man

    9/3/25 11:37:00 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Announces Public Offering of $600 Million of Mandatory Convertible Preferred Stock

    Bruker Corporation ("Bruker") (NASDAQ:BRKR) today announced it has commenced a public offering, subject to market and other conditions, of $600.0 million of Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the "Mandatory Convertible Preferred Stock"). Bruker expects to grant the underwriters a 30-day option to purchase up to an additional $90.0 million of Mandatory Convertible Preferred Stock, solely to cover over-allotments, if any. Bruker intends to use the net proceeds from this offering to strengthen the balance sheet and enhance strategic flexibility by repaying (i) its term loan due December 2026 in full, (ii) outstanding borrowings under its 2024 amended

    9/2/25 4:01:00 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Announces Quarterly Dividend

    Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on October 3, 2025 to stockholders of record as of September 23, 2025. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and

    8/12/25 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CEO Laukien Frank H bought $100,043 worth of shares (2,608 units at $38.36), increasing direct ownership by 0.01% to 38,462,171 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    6/9/25 4:15:11 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Accounting Officer Bures Thomas bought $23,698 worth of shares (500 units at $47.40), increasing direct ownership by 17% to 3,472 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    3/11/25 4:11:27 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PRESIDENT & CEO Laukien Frank H bought $1,018,330 worth of shares (20,000 units at $50.92), increasing direct ownership by 0.05% to 38,459,563 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    2/19/25 4:23:26 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CEO Laukien Frank H was granted 48,431 shares, increasing direct ownership by 0.13% to 38,494,103 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    8/19/25 4:15:28 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PRESIDENT, BIOSPIN GROUP Busse Falko was granted 9,282 shares, increasing direct ownership by 24% to 48,171 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    8/19/25 4:15:25 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EXEC VP&PRES BRUKER NANO INC. Munch Mark was granted 23,631 shares, increasing direct ownership by 23% to 128,443 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    8/19/25 4:15:20 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bruker downgraded by Citigroup with a new price target

    Citigroup downgraded Bruker from Buy to Neutral and set a new price target of $40.00

    5/22/25 8:18:13 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Guggenheim initiated coverage on Bruker with a new price target

    Guggenheim initiated coverage of Bruker with a rating of Buy and set a new price target of $72.00

    12/19/24 7:30:10 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    UBS initiated coverage on Bruker with a new price target

    UBS initiated coverage of Bruker with a rating of Neutral and set a new price target of $66.00

    12/10/24 8:26:42 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Leadership Updates

    Live Leadership Updates

    View All

    Solis Agrosciences Names Crystal Winkeler Chief Business Officer to Drive Commercial Growth

    ST. LOUIS, April 23, 2025 (GLOBE NEWSWIRE) -- Solis Agrosciences, the trusted partner for high-quality AgTech research services, announced that it has hired Crystal Winkeler as Chief Business Officer. Winkeler will join Solis on May 1 to drive the company's commercial team and help lead efforts to develop and acquire new offerings. "Solis has assembled an impressive team, offerings, and customer base," said Winkeler. "I am thrilled to join the business at this important growth stage." "Crystal is a proven talent who is confident, capable, and credible in front of customers and stakeholders," said Charlie Bolten, CEO of Solis Agrosciences. "She is a huge addition and will help drive our c

    4/23/25 6:15:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Appoints Laura Francis to its Board of Directors

    Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

    2/21/25 8:00:00 AM ET
    $BRKR
    $PGNY
    $SIBN
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Misc Health and Biotechnology Services
    Health Care

    Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

    Strategic partnership expands Biognosys' services to include Alamar's NULISA assays as well as joint scientific research in biofluid-based proteomicsComplementary value of Biognosys' DIA-MS unbiased proteomics platform and Alamar's game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomic

    4/4/24 8:11:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Financials

    Live finance-specific insights

    View All

    Bruker Announces Quarterly Dividend

    Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on October 3, 2025 to stockholders of record as of September 23, 2025. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and

    8/12/25 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Announces Second Quarter 2025 Preliminary Results, Plans to Hold Q2 Earnings Conference Call on August 4, 2025

    Bruker Corporation (NASDAQ:BRKR) today announced preliminary revenue for the second quarter ended June 30, 2025 in a range of $795 - $798 million, which implies approximately flat reported revenue year-over-year. Bruker estimates that its non-GAAP organic revenue in the second quarter of 2025 declined approximately 7% year-over-year, with constant-exchange rate revenue declining approximately 3%. Second quarter 2025 bookings reflect weak academic demand, as well as softness in the U.S. biopharma market. Second quarter 2025 non-GAAP EPS is expected in the $0.32 - $0.34 range, representing approximately a $0.19 per share decline year-over-year, including a $0.06 foreign currency headwind.

    7/21/25 8:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Announces Acquisition of biocrates, a Leader in Mass Spectrometry-based Quantitative Metabolomics

    Acquisition further expands Bruker's multiomics strategy with biocrates metabolomics kits and assays, and related software and research services Bruker Corporation (NASDAQ:BRKR) today announced the acquisition of biocrates life sciences ag, located in Innsbruck, Austria. Financial terms were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603323690/en/biocrates kits and pipettes biocrates is a global leader in mass spectrometry (MS)-based quantitative metabolite and lipid analysis kits, assays, software and services that make standardized metabolomics accessible to laboratories worldwide. The biocrates kits co

    6/3/25 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    SC 13G/A - BRUKER CORP (0001109354) (Subject)

    11/14/24 1:28:29 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    SC 13G/A - BRUKER CORP (0001109354) (Subject)

    11/13/24 6:01:26 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    SC 13G/A - BRUKER CORP (0001109354) (Subject)

    11/12/24 11:54:03 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    SEC Filings

    View All

    SEC Form CERT filed by Bruker Corporation

    CERT - BRUKER CORP (0001109354) (Filer)

    9/8/25 4:56:01 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 8-A12B filed by Bruker Corporation

    8-A12B - BRUKER CORP (0001109354) (Filer)

    9/8/25 4:40:42 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Corporation filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - BRUKER CORP (0001109354) (Filer)

    9/8/25 4:21:37 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials